(877) 636-4978

Press Room



Recent News

Today, our research tools and technologies are transforming stem cell-based research. With the great promise of stem cell therapeutics to treat, and possibly cure, a broad range of human diseases. At ESI BIO, with the support of our parent company BioTime, Inc., we focus on developing research reagents that are translatable to the clinical. Follow our progress as we work to make this exciting and unique vision a reality.

December 15, 2014

ESI and GE Healthcare Cross-License patents

BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing


May 23, 2014

ESI BIO's HyStem® Hydrogels featured on Biocompare

Article Includes Bench Tips for Optimizing 3D Cell Culture with Customizable Hydrogels

April 23, 2014

ESI BIO Launches New Website

BioTime Division ESI BIO Launches New Responsive Design Website to the Scientific Community


October 28, 2013

BioTime Organizes New ESI BIO Division

BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products - Appoints Jeffrey Janus as CEO of ES Cell International Pte Ltd.


August 19, 2011

NIH Approved ESI Human Embryonic Stem Cells

BioTime Receives NIH Approval for Four GMP Human Embryonic Stem Cell Lines: ESI-035, ESI-049, ESI-051 and ESI-053 approved for use in federally funded research


May 3, 2010

BioTime, Inc. Announces Completion of ES Cell International Pte Ltd Acquisition

Acquisition to Accelerate Development of Research and Therapeutic Products


Join the Conversation on Twitter